Get the Stockscreener App
0.00
100.00%
-4.36
Adverum Biotechnologies Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
See More
Previous Close:
$4.36
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$96.26M
Revenue:
-
Net Income/Loss:
$-94.11M
P/E Ratio:
0.00
EPS:
-6.01
Net Cash Flow:
$-86.06M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$5.75
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Name
Adverum Biotechnologies Inc
Sector
Industry
Phone
(650) 649-1004
Address
100 CARDINAL WAY, REDWOOD CITY, CA
Compare ADVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
0.00 | 96.26M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.50 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
805.12 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
402.46 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
799.10 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
172.04 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Upgrade | Truist | Hold → Buy |
| Jul-23-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-03-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-29-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-29-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-29-21 | Downgrade | Truist | Buy → Hold |
| Dec-16-20 | Initiated | UBS | Neutral |
| Nov-12-20 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jun-26-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-05-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-16-20 | Initiated | SVB Leerink | Outperform |
| Feb-10-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-10-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Neutral |
| Sep-13-19 | Reiterated | Chardan Capital Markets | Neutral |
| Jun-14-19 | Resumed | Raymond James | Mkt Perform |
| Nov-02-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-02-18 | Downgrade | SunTrust | Buy → Hold |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-30-18 | Initiated | SunTrust | Buy |
| Feb-15-18 | Resumed | Piper Jaffray | Overweight |
| Oct-12-17 | Initiated | Raymond James | Outperform |
View All
Adverum Biotechnologies Inc Stock (ADVM) Latest News
Is Adverum Biotechnologies Inc. stock a dividend growth opportunity2025 Performance Recap & Community Driven Trade Alerts - ulpravda.ru
What drives Adverum Biotechnologies Inc stock priceValue Stock Picks & Capital Planning and Optimization - earlytimes.in
ADVM stock touches 52-week low at $4.01 amid market challenges - MSN
Adverum Biotechnologies, Inc. Financial Disclosures & Filings - TradingView — Track All Markets
Adverum Biotechnologies (NASDAQ:ADVM) Stock Price Passes Above 50 Day Moving Average – Time to Sell? - Defense World
Is Adverum Biotechnologies Inc. (AVU0) stock trading at attractive multiplesJuly 2025 Catalysts & Short-Term High Return Ideas - Bölüm Sonu Canavarı
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $10.50 Average PT from Brokerages - Defense World
What catalysts could drive Adverum Biotechnologies Inc. stock higherJuly 2025 Chart Watch & Fast Momentum Entry Tips - Улправда
Why Adverum Biotechnologies Inc. stock is rated strong buyWeekly Trend Report & Free Long-Term Investment Growth Plans - DonanımHaber
Why Adverum Biotechnologies Inc. stock is in analyst buy zoneJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - DonanımHaber
Investor Mood: Why Adverum Biotechnologies Inc stock is in analyst buy zoneJuly 2025 Review & Precise Swing Trade Entry Alerts - moha.gov.vn
Adverum Biotechnologies releases promising phase 2 trial data - MSN
Adverum Biotechnologies Earnings Notes - Trefis
Adverum Biotechnologies, Inc. Stock ()Quote BOERSE BERLIN - marketscreener.com
Adverum Biotechnologies (NASDAQ:ADVM) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Lowered to “Strong Sell” Rating by Wall Street Zen - Defense World
Market Catalysts: Why hedge funds are buying Adverum Biotechnologies Inc stockJuly 2025 Spike Watch & Consistent Return Investment Signals - moha.gov.vn
Hedge Fund and Insider Trading News: Cathie Wood, Michael Burry, Renaissance Technologies, Mason Capital, Millennium Management, Adverum Biotechnologies Inc (ADVM), MGM Resorts International (MGM), and More - Insider Monkey
Adverum Biotechnologies, Inc.(NasdaqCM: ADVM) dropped from S&P TMI Index - marketscreener.com
Eli Lilly completes acquisition of Adverum Biotechnologies - MSN
CEO Fischer Acquires 650,000 Of Adverum Biotechnologies Inc [ADVM] - TradingView — Track All Markets
Lilly moves forward with $3.56-per-share acquisition of Adverum - Indian Pharma Post
Lilly completes tender offer for Adverum Biotechnologies By Investing.com - Investing.com Australia
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition - The AI Journal
Lilly completes tender offer for Adverum Biotechnologies - Investing.com India
Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook - ts2.tech
Eli Lilly (LLY) Completes Acquisition of Adverum Biotechnologies - GuruFocus
Eli Lilly Moves Forward With Acquisition Of Adverum Biotechnologies - Nasdaq
Monday’s Insider Moves: Adverum Execs Lead Buys, Diamondback Sale Tops - Investing.com Australia
Adverum Biotechnologies Stock (ADVM) Opinions on Lilly Acquisition - Quiver Quantitative
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition | Eli Lilly and Company - Eli Lilly
Lilly completes Adverum acquisition for $3.56 per share plus CVRs - StreetInsider
Laurent Fischer Acquires 117,614 Shares of Adverum Biotechnologies (NASDAQ:ADVM) Stock - MarketBeat
Insider Buying: Laurent Fischer Acquires Shares of Adverum Biote - GuruFocus
Soparkar Peter, Adverum Biotechnologies COO, buys $211k in shares By Investing.com - Investing.com Canada
Adverum biotechnologies CEO Fischer buys shares worth $553916 By Investing.com - Investing.com Canada
Adverum Biotechnologies Executives Increase Stake in Company - TradingView — Track All Markets
CEO Fischer Buys 128,699 ($553.9K) Of Adverum Biotechnologies Inc [ADVM] - TradingView — Track All Markets
Adverum Biotechnologies, Inc.(NasdaqGM: ADVM) dropped from NASDAQ Composite Index - marketscreener.com
Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells $2,197,906.40 in Stock - Defense World
null - Trefis
Adverum Biotechnologies, Inc.(NasdaqCM: ADVM) dropped from Russell Microcap Index - marketscreener.com
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) dropped from Russell Microcap Value Index - marketscreener.com
Insider Selling: Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells $2,197,906.40 in Stock - MarketBeat
What analysts say about Adverum Biotechnologies Inc stockEarnings Per Share Trends & Try Our Free Strategy Builder Now - earlytimes.in
Owner Leonard Sells 524,560 ($2.2M) Of Adverum Biotechnologies Inc [ADVM] - TradingView
Adverum Reminds Stockholders to Tender Their Shares Into the Offer by Lilly - 富途牛牛
LUNA Surges 20% in a Day Amid Ongoing Terra Network Upgrade - Bitget
Why retail traders accumulate Adverum Biotechnologies Inc. (AVU0) stockWeekly Profit Report & Advanced Swing Trade Entry Alerts - Newser
Insider Selling: Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells 222,925 Shares of Stock - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Braden Michael Leonard Sells 51,961 Shares - MarketBeat
Adverum Biotechnologies Inc Stock (ADVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):